PURPOSE: [(11)C]Flumazenil shows promise as a clinical and research PET radiotracer to image changes in GABA(A) central benzodiazepine receptor (cBZR), but its widespread use has been limited by practical limitations of [(11)C]. This study evaluated the imaging characteristics of two fluorinated PET radiotracers in rats in vivo: [(18)F]fluoroflumazenil ([(18)F]FFMZ) and [(18)F]flumazenil ([(18)F]FMZ). METHODS: PET acquisitions were performed on a small-animal scanner following injection of [(18)F]FFMZ in nine rats and [(18)F]FMZ in eight rats. The following treatments were investigated: (1) injection of the tracer dose, (2) presaturation then injection of the tracer dose, and (3) injection of the tracer dose followed by a displacement injection. Unchanged tracer was measured in plasma and brain structures in four animals 10 and 30 min after injection, and ex-vivo autoradiography was also performed. RESULTS: For both [(18)F]FFMZ and [(18)F]FMZ maximal brain activity peaked rapidly, and was highest in the hippocampus (1.12+/-0.06 SUV, 1.24+/-0.10 SUV, respectively), and lowest in the pons (1.00+/-0.07 SUV, 1.03+/-0.09 SUV, respectively). By 50 min after injection, maximal uptake for [(18)F]FFMZ and [(18)F]FMZ had decreased in the hippocampus to 18+/-3% and 80+/-1% (p<0.01), respectively. The presaturation and displacement studies showed a higher nonspecific component for [(18)F]FFMZ than for [(18)F]FMZ. Metabolite studies showed that at 30 min only 10% of the signal was from [(18)F]FFMZ in the brain. This nonspecific binding was apparent on autoradiography. In contrast, [(18)F]FMZ accounted for >70% of the signal in the brain, which resulted in well-defined regional binding on autoradiography. CONCLUSION: These results demonstrate that [(18)F]FMZ is a superior radiotracer to [(18)F]FFMZ for in-vivo PET imaging of the GABA(A)/cBZR, having slower metabolism and leading to lower concentrations of metabolites in the brain that results in a substantially better signal-to-noise ratio.
PURPOSE: [(11)C]Flumazenil shows promise as a clinical and research PET radiotracer to image changes in GABA(A) central benzodiazepine receptor (cBZR), but its widespread use has been limited by practical limitations of [(11)C]. This study evaluated the imaging characteristics of two fluorinated PET radiotracers in rats in vivo: [(18)F]fluoroflumazenil ([(18)F]FFMZ) and [(18)F]flumazenil ([(18)F]FMZ). METHODS: PET acquisitions were performed on a small-animal scanner following injection of [(18)F]FFMZ in nine rats and [(18)F]FMZ in eight rats. The following treatments were investigated: (1) injection of the tracer dose, (2) presaturation then injection of the tracer dose, and (3) injection of the tracer dose followed by a displacement injection. Unchanged tracer was measured in plasma and brain structures in four animals 10 and 30 min after injection, and ex-vivo autoradiography was also performed. RESULTS: For both [(18)F]FFMZ and [(18)F]FMZ maximal brain activity peaked rapidly, and was highest in the hippocampus (1.12+/-0.06 SUV, 1.24+/-0.10 SUV, respectively), and lowest in the pons (1.00+/-0.07 SUV, 1.03+/-0.09 SUV, respectively). By 50 min after injection, maximal uptake for [(18)F]FFMZ and [(18)F]FMZ had decreased in the hippocampus to 18+/-3% and 80+/-1% (p<0.01), respectively. The presaturation and displacement studies showed a higher nonspecific component for [(18)F]FFMZ than for [(18)F]FMZ. Metabolite studies showed that at 30 min only 10% of the signal was from [(18)F]FFMZ in the brain. This nonspecific binding was apparent on autoradiography. In contrast, [(18)F]FMZ accounted for >70% of the signal in the brain, which resulted in well-defined regional binding on autoradiography. CONCLUSION: These results demonstrate that [(18)F]FMZ is a superior radiotracer to [(18)F]FFMZ for in-vivo PET imaging of the GABA(A)/cBZR, having slower metabolism and leading to lower concentrations of metabolites in the brain that results in a substantially better signal-to-noise ratio.
Authors: G Gründer; T Siessmeier; C Lange-Asschenfeldt; I Vernaleken; H G Buchholz; P Stoeter; A Drzezga; H Lüddens; F Rösch; P Bartenstein Journal: Eur J Nucl Med Date: 2001-10
Authors: Young Soo Chang; Jae Min Jeong; Young Hyun Yoon; Won Jun Kang; Seung Jin Lee; Dong Soo Lee; June-Key Chung; Myung Chul Lee Journal: Nucl Med Biol Date: 2005-04 Impact factor: 2.408
Authors: Sami S Zoghbi; H Umesha Shetty; Masanori Ichise; Masahiro Fujita; Masao Imaizumi; Jeih-San Liow; Jay Shah; John L Musachio; Victor W Pike; Robert B Innis Journal: J Nucl Med Date: 2006-03 Impact factor: 10.057
Authors: Markus Mitterhauser; Wolfgang Wadsak; Leila Wabnegger; Leonhard-Key Mien; Stefan Tögel; Oliver Langer; Werner Sieghart; Helmut Viernstein; Kurt Kletter; Robert Dudczak Journal: Nucl Med Biol Date: 2004-02 Impact factor: 2.408
Authors: M Kessler; M Mamach; R Beutelmann; M Lukacevic; S Eilert; P Bascuñana; A Fasel; F M Bengel; J P Bankstahl; T L Ross; G M Klump; G Berding Journal: Mol Imaging Biol Date: 2020-04 Impact factor: 3.488
Authors: Isadora Lopes Alves; David Vállez García; Andrea Parente; Janine Doorduin; Rudi Dierckx; Ana Maria Marques da Silva; Michel Koole; Antoon Willemsen; Ronald Boellaard Journal: EJNMMI Res Date: 2017-02-22 Impact factor: 3.138
Authors: Martin Mamach; Mariella Kessler; Jens P Bankstahl; Florian Wilke; Lilli Geworski; Frank M Bengel; Simone Kurt; Georg Berding Journal: PLoS One Date: 2018-10-02 Impact factor: 3.240